Showing 9231-9240 of 20873 results for "".
EMPOWER - Practice Efficiency and Innovation
https://reachmd.com/podcasts/the-mod-pod/empower-practice-efficiency-and-innovation/45566/In the 2025 summary podcast hosted by Dr. Jacob Lang, Dr. Diana Chu shares practical, technology-driven strategies to streamline operations, improve patient flow, and strengthen team communication. Dr. Jason Compton discusses how independent practices can thrive through cash-pay models, automation,Dermwire TV: Ruxolitinib Cream 1.5% Effective for AD Improvement, Stapokibart Shows Promise
https://reachmd.com/videos/dermwire-tv/dermwire-tv-ruxolitinib-cream-15-effective-for-ad-improvement-stapokibart-shows-promise/49101/This episode highlights new research showing ruxolitinib cream 1.5% providing itch relief and broader atopic dermatitis (AD) improvement, as well as a post-hoc analysis finding safety and efficacy for stapokibart in elderly adults with AD; and Excellergy executives discuss how recent research validaPrecision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
https://reachmd.com/clinical-practice/cardiology/precision-medicine-in-obstructive-hcm-care-the-promise-of-cardiac-myosin-inhibitors/48692/Explore the promise of cardiac myosin inhibitors and how they are marking a paradigm shift in obstructive HCM Care.Interdisciplinary Management of Gynecologic Cancers
https://reachmd.com/programs/cme/Interdisciplinary-Management-of-Gynecologic-Cancers/39286/Multidisciplinary experts explore biomarker-driven strategies, immunotherapy, and personalized care in cervical and endometrial cancer management.Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
https://reachmd.com/programs/neurofrontiers/examining-inebilizumab-in-generalized-myasthenia-gravis-insights-from-mint/32859/Even though the available therapeutic options for generalized myasthenia gravis (gMG) have improved outcomes, challenges like incomplete responses, treatment fatigue, and side-effect burdens remain. That's why the MINT trial, published in The New England Journal of Medicine in June 2025, explored thImproving Lipid Management Through Equity-Focused Clinical Strategies
https://reachmd.com/programs/heart-matters/improving-lipid-management-through-equity-focused-clinical-strategies/37598/Despite advances in lipid-lowering therapies, disparities in hyperlipidemia diagnosis and treatment persist. Dr. Keith Ferdinand examines how social drivers of health impact access, adherence, and outcomes and explains how clinicians can help address gaps in care for underserved populations. Dr. FerOverview of the Latest Guidance in IgA Nephropathy Management
https://reachmd.com/programs/kdigo-conversations-nephrology/overview-of-the-latest-guidance-in-iga-nephropathy-management/37115/On this first episode of the KDIGO IgA Nephropathy (IgAN) podcast series, join host Dr. Dana Rizk and special guest Dr. Brad Rovin for a discussion on the latest guidance for managing IgAN. As an expert in glomerular diseases and co-chair of the KDIGO Glomerular Disease Guideline Working Group, Dr.Improving Post-Surgical Outcomes With Proactive, Multidisciplinary Care
https://reachmd.com/programs/clinicians-roundtable/improving-post-surgical-outcomes-with-proactive-multidisciplinary-care/36433/Communication breakdowns during care transitions can compromise recovery—but they’re often preventable. Initiating multidisciplinary planning before surgery can help streamline post-surgical wound and skin management. Hear from Dr. Karen Bauer as she explains how how proactive use of care navigaImproving Metastatic Breast Cancer Care Through Integrated Palliative Support
https://reachmd.com/programs/frontlines-metastatic-breast-cancer/improving-metastatic-breast-cancer-care-through-integrated-palliative-support/36436/A 2025 study conducted at Champalimaud Clinical Center’s Breast Unit in Portugal explored the impacts of a fully embedded palliative care model for patients with metastatic breast cancer. In this AudioAbstract, Mr. Ryan Quigley dives into the findings on how proactive, integrated support may enhEvaluating Guselkumab for Pediatric Psoriasis: New Phase III Trial Data
https://reachmd.com/programs/dermconsult/evaluating-guselkumab-for-pediatric-psoriasis-new-phase-iii-trial-data/32450/The phase III PROTOSTAR study published in the Journal of the American Academy of Dermatology in March 2025 highlights new findings on the efficacy and safety of guselkumab for pediatric psoriasis. Join Dr. Amy Paller as she reviews the data and its implications for the future of pediatric psoriasis